Abstract

Objectives

To determine the serum expression levels of seven candidate microRNAs (miRNA); miR-19a, miR-19b, miR-29a, miR-29c, miR-181, miR-195 and miR-221 in Turkish patients with Parkinson’s disease (PD) and explored their potential role in the diagnosis of PD. We further described the relationship between these miRNAs with the clinical findings and treatment of PD.

Materials and methods

The study included 51 PD patients and 20 healthy controls. The clinical severity of disease was assessed using the Hoehn Yahr staging scale and the Unified Parkinson’s Disease Rating Scale (UPDRS). Venous blood samples were taken after fasting for 12 h, then centrifuged. Obtained serum samples were stored until analysis of miRNA. In the laboratory, expression levels of these miRNAs were analyzed using a real-time PCR instrument. Receiver-operating characteristic analysis and area-under the-curve (AUC) was used to evaluate these miRNA levels as potential diagnostic biomarkers for PD.

Results

miR-29c expression levels were increased significantly for PD patients compared to healthy controls. There were no significant differences in levels of other miRNAs between PD patients and controls. The AUC of miR-29c was 0.689. The sensitivity and specificity of this diagnostic test was 54.9% and 80.0%, respectively. miR-195 level was found to have a significant positive correlation only with age. Significant negative correlation was found between miR-29a level and UPDRS total score. miR-19b was found higher in ropinirole drug used group than that of pramipexole group.

Conclusion

This study suggests that serum miR-29c expression level might be potential biomarker in the diagnosis of Turkish Parkinson patients.

中文翻译：

---

土耳其帕金森病患者的血清 microRNA 表达水平

摘要

目标

确定七种候选微小RNA（miRNA）的血清表达水平；miR-19a、miR-19b、miR-29a、miR-29c、miR-181、miR-195 和 miR-221 在土耳其帕金森病 (PD) 患者中的应用，并探讨了它们在 PD 诊断中的潜在作用。我们进一步描述了这些 miRNA 与 PD 的临床发现和治疗之间的关系。

材料和方法

该研究包括 51 名 PD 患者和 20 名健康对照。使用 Hoehn Yahr 分期量表和统一帕金森病评定量表 (UPDRS) 评估疾病的临床严重程度。禁食 12 h 后取静脉血样，然后离心。储存获得的血清样品，直到分析 miRNA。在实验室中，使用实时 PCR 仪器分析了这些 miRNA 的表达水平。接受者操作特征分析和曲线下面积 (AUC) 用于评估这些 miRNA 水平作为 PD 的潜在诊断生物标志物。

结果

与健康对照相比，PD 患者的 miR-29c 表达水平显着增加。PD 患者和对照组之间其他 miRNA 的水平没有显着差异。miR-29c 的 AUC 为 0.689。该诊断测试的敏感性和特异性分别为 54.9% 和 80.0%。发现miR-195水平仅与年龄呈显着正相关。miR-29a水平与UPDRS总分呈显着负相关。miR-19b在罗匹尼罗用药组高于普拉克索组。

结论

本研究表明，血清 miR-29c 表达水平可能是土耳其帕金森患者诊断的潜在生物标志物。